ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS
Boost For Lilly, Blow For Pfizer
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.
